

Table S1 TARE-related adverse events

Adverse events	CTCAE grade	Outcome
Transient increase in serum bilirubin levels	Grade 1 (n=2)	Favorable outcome without any treatment
Lymphocytopenia	Grade 1 (n=7)	Favorable outcome without any treatment
	Grade 2 (n=2)	
	Grade 3 (n=4)	
Radioembolization-induced gastric ulcers	Grade 2 (n=2 [†])	Favorable outcome with medical treatment

[†], one patient had a right flow redistribution during a left lobar treatment and the other patient had an accessory pyloric artery not seen during the pretreatment phase. CTCAE, common terminology criteria for adverse events; TARE, transarterial radioembolization.

Table S2 Baseline and pre-operative data on biochemical liver function tests and CHILD/MELD scores

Variables	Baseline values	Pre-operative values
Biological data		
PT (%)	84 [47–100]	91 [40–100]
Albumin (g/L)	43 [36–49]	42 [34–48]
Platelets (cells/ μ L)	184 [55–462]	161 [53–321]
Bilirubin levels (μ mol/L)	10.5 [6–36]	9 [3–51]
AST (UI/L)	42 [17–140]	27 [18–79]
ALT (UI/L)	33 [11–143]	25 [11–120]
Child-Pugh score	5 [5–6]	5 [5–7]
MELD score	7 [6–16]	7 [6–18]

The data are expressed as n [%] or median [range]. PT, prothrombin time; AST, aspartate transaminase; ALT, alanine transaminase; MELD, Model for End-Stage Liver Disease.

Table S3 Data specific to patients with portal vein tumoral thrombus

Variables	Values
Surgery type	
Liver transplantation	2 [14]
Right hepatectomy	8 [57]
Left lobectomy	2 [14]
Less extended surgery	2 [14]
AFP	
Baseline	15.5 [2.2–3,071]
3 months after TARE	11 [1.9–85]
Tumor absorbed dose (Gy)	
Pre-treatment SPECT-CT	320 [31–1,131]
Post-treatment PET-CT	377 [170–967]
Localized mRECIST	
CR	6 [43]
PR	7 [50]
SD	1 [7]
mRECIST	
CR	6 [43]
PR	5 [36]
SD	1 [7]
PD	2 [14]
Pathological necrosis	
CPN	5 [36]
Extensive	8 [57]
Partial	1 [7]
Microvascular emboli	4 [29]
Incomplete pathological necrosis on the PVTT	3 [21]
Time to surgery (months)	6.7 [2.1–14.6]
Recurring patients	5 [36]
Time to recurrence (months)	21.5 [10.3–49.3]
Deceased patients	4 [29]

The data are expressed as n [%] or median [range]. AFP, alpha fetoprotein; PET, positron emission tomography; SPECT, Single photon emission computed tomography; CT, computed tomography; mRECIST, modified response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PVTT, portal vein tumor thrombus; TARE, transarterial radioembolization; CPN, complete pathological necrosis.